Anticytokine autoantibodies in a patient with a heterozygous NFKB2 mutation
To the Editor:
Germline heterozygous NFKB2 variants that result in an unprocessable NF-kB2 (nuclear factor-kappa-B) p100 subunit have been identified as a cause of primary immunodeficiency. 1 Patients often present with clinical and immunological features consistent with common variable immunodeficiency (CVID); however, additional defects in T and natural killer cells have been reported, widening the immunological phenotype. Multisystem autoimmunity is also frequently present in patients with damaging NFKB2 variants, causing endocrinopathies including central adrenal insufficiency, growth hormone deficiency, and hypothyroidism, as well as cutaneous autoimmune manifestations of alopecia totalis and trachyonychia.
A 2-year-old female (II.2) presented with polyuria, polydipsia, dehydration, and dyselectrolytemia. A renal biopsy showed interstitial nephritis with polyclonal B and T lymphocytic infiltrate and she was diagnosed with proximal renal tubular acidosis. She had a history of a sterile dry cough since birth and chest imaging was consistent with an interstitial pneumonitis. The renal tubular acidosis and cough improved with a prolonged weaning course of oral corticosteroid, but she began to suffer repeated bacterial infections, extensive molluscum contagiosum over the lower half of her body, and developed alopecia totalis and trachyonychia. Imaging confirmed bilateral bronchiectasis and immunological investigation showed panhypogammaglobulinemia, poor response to polysaccharide vaccine, CD4
1 T lymphocytosis, poor differentiation of memory T cells, and reduced class-switched memory phenotype (see Table E1 in this article's Online Repository at www.jacionline.org). She was diagnosed with CVID, and replacement therapy with subcutaneous immunoglobulin was commenced. However, she developed recurrent deep-seated pyogenic bacterial infections throughout childhood and early teenage years, which included a deep abscess in the left proximal tibia complicated by septic arthritis of the hip, septic arthritis of the right knee, and osteomyelitis of the left pubic ramus, and prepatellar bursitis and bacterial cellulitis of the right thigh with associated bacteremia. She also suffered repeated viral infections, including influenza pneumonitis and respiratory failure that was considered atypically for a predominant antibody deficiency (see Fig E1 in this article's Online Repository at www.jacionline.org).
The index patient's (II.2) father (I.1) also had a history of recurrent sinopulmonary infections throughout childhood. At 23 years he was diagnosed with EBV-negative nasopharyngeal non-Hodgkin lymphoma, which was successfully treated to complete remission with chemotherapy. He continued to suffer recurrent bacterial respiratory tract infections, and immunological investigation led to a diagnosis of CVID, although I.1 has remained well and asymptomatic since his lymphoma treatment with no current therapeutic interventions despite mild hypogammaglobulinemia (Fig 1 and Table E1 ).
Because of the autosomal-dominant pattern of inheritance of CVID within the family, genetic investigation was performed. Whole-exome sequencing and Sanger sequencing confirmation identified a heterozygous NFKB2 NM_001077494.2 c.2557C>T:p.Arg853Ter variant that resulted in a truncated NF-kB2 p100 subunit to be present in the I.1 and II.2 (Fig 1; see Figs E2 and E3 in this article's Online Repository at www.jacionline.org).
Because of disease severity discordance between I.1 and II.2, further immunological investigations were performed. These identified the presence of anti-IFN-a, IFN-b, IFN-v, IL-12p40, and IL-23 anticytokine autoantibodies (ACAAs) in the serum of II.2. No ACAAs were found in serum from I.1 (Fig 2; see this article's Methods section in the Online Repository at www.jacionline.org).
In light of these findings, we treated II. The development and pattern of ACAAs, as well as clinical feature of alopecia and trachyonychia, observed in II.2 is reminiscent of that of autoimmune polyendocrinopathycandidasis-ectodermal dysplasia (APECED) and thymoma patients in whom there is impairment of thymic medullary function, resulting in autoimmunity (Fig 2, B) .
2 Correct function of the NF-kB2 pathway is required to establish the thymic medullary compartment and correctly regulate AIRE expression.
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Lym12/2 knockout mice also show significant impairment of medullary thymic epithelial cell maturation and AIRE expression, leading to the development of autoantibodies. 4 Therefore, we hypothesize that errant thymic function in patients with heterozygous NFKB2 mutations may led to ACAAs and the broad organ-specific autoimmunity, including the cutaneous manifestations, which are present in this patient group. 1 ACAAs have been reported in other primary immunodeficiencies, including patients with biallelic hypofunctional RAG variants in whom neutralizing anti-IFN-a, IFN-v, and IL-12 autoantibodies were associated with increased susceptibility to viral infections. 5 IFN-a, IFN-v, and IL-12p40 ACAAs were present in II.2, and we may postulate that it is similarly also underlying medullary thymic epithelial cell impairment in patients with hypofunctional RAG genes, AIRE deficiency, and thymoma that leads to the development of this specific ACAA pattern. 6 However, the precise role of neutralizing ACAAs in health and disease remains elusive with the presence of neutralizing type 1 IFN ACAAs potentially conveying a beneficial protective counterbalance in those at high risk of, or suffering, autoimmune diseases. 7, 8 Following rituximab treatment we observed a clinical improvement with a reduction in infections despite not all ACAAs measured displaying a significant reduction (Fig E4) . Given the broad range of ACAAs that have been previously reported, it may be that still unidentified ACAAs or anticytokine receptor autoantibody levels were concurrently reduced by rituximab therapy, contributing to partial restoration of immunological function and the overall resultant clinical improvement.
9 IL-12p40 ACAAs did not significantly decline post-rituximab and therefore we remain vigilant for potential intracellular pathogens although the infectious risks of anti-IL-12 autoantibodies remain unclear.
9
In conclusion, patients with heterozygous NFKB2 variants may develop ACAAs because of impaired thymic central tolerance, resulting in a more severe clinical phenotype and autoimmunity. Screening of these patients for ACAAs and treatment with rituximab may offer therapeutic benefits.
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To the Editor:
Atopic dermatitis (AD) is a common skin disease in children. While genetic predisposition and environmental factors are accepted mediators of AD development, the role of the innate immune system is not yet completely elucidated. Likely mediators of AD are nucleotide-binding oligomerization and pyrin domain containing-receptors (NLRPs), which are involved in the innate immune response. 1 So far, few studies investigated the role of NLRPs in adult AD, primarily focusing on single nucleotide polymorphisms (SNPs), while only reporting transcriptional changes for NLRP2 and NLRP3. 2, 3 To elucidate the relevance of NLRPs in childhood AD, this study focused on these 2 NLRP family members.
We started by evaluating the transcription of NLRP2 and NLRP3 in whole blood of children of the Lifestyle and Environmental Factors and Their Influence on Newborns Allergy Risk (LINA) cohort (see Fig E1 in this article' s Online Repository at www.jacionline.org), showing AD symptoms or were diagnosed with AD by a physician until the age of 6 years (''AD ever'') (Fig 1; see also Table E1 and Fig E1 in this article' s Online Repository at www.jacionline.org). While NLRP3 expression was unaltered, NLRP2 was decreased in 1-year-old children with AD compared with healthy controls (Fig 1, A; see also Tables E2  and E3 in this article's Online Repository at www.jacionline.org).
Since there are different pheno-and endotypes of AD, supposedly based on different molecular and cellular characteristics, we further separated the occurrence of AD into early-and late-onset (see Fig E2 in this article' s Online Repository at www. jacionline.org). Only for children with early-onset AD was NLRP2 differentially expressed in comparison to healthy controls (Fig 1, B, Tables E2 and E3 ). NLRP3 was neither differentially transcribed in early-nor late-onset AD compared with controls (Tables E2 and E3) .
As DNA-methylation is as a potent epigenetic regulator of gene expression, we next investigated NLRP2 promoter methylation. Using whole genome bisulfite sequencing data from cord blood samples of a subset of children from our cohort, we observed NLRP2 promoter hypermethylation in children with early-onset AD compared with controls (Fig 2, A; see also Table  E4 in this article's Online Repository at www.jacionline.org).
Validation of DNA-methylation (see Fig E3 and Table E5 in this article's Online Repository at www.jacionline.org) in the entire cohort confirmed an AD-related promoter hypermethylation at birth and at age 1 year, which was associated with an increased risk for the children to develop early-onset AD (Fig  2, B) . At both time points this hypermethylation was inversely correlated with NLRP2 transcription (see Fig E4 in this article' s Online Repository at www.jacionline.org), suggesting a functional translation of the methylation change to the transcriptional level.
Subsequently, we investigated whether the alterations in NLRP2 expression and methylation arose from a specific blood cell subpopulation. Although monocytes, B cells, CD8
1
, and CD4
1 T cells of children with AD showed a significant difference in NLRP2 expression and methylation compared with controls, the pattern was similar in all subpopulations, suggesting that AD-associated differences in NLRP2 are not related to changes in these specific cell types (see Fig E5 in this article' s Online Repository at www.jacionline.org).
Another level, by which variation in gene expression can be explained are expression quantitative trait loci (eQTLs). Because the Genotype-Tissue-Expression portal describes rs514148 as the most significant eQTL for NLRP2 in blood, we analyzed this SNP in our cohort. Both NLRP2 transcription and promoter methylation were different between rs514148 genotypes (see Fig E6 in this article's Online Repository at www.jacionline.org), characterizing rs514148 also as a methylation QTL for NLRP2.
Reevaluating our AD-related regression analyses by including the rs514148 variant as a confounder retained the significant risk increase for AD development in relation to NLRP2 repression and promoter hypermethylation (age 1 year: transcription, adjusted odds ratio [adj OR] 5 0.75, 95% CI: 0.62-0.91; methylation, adj OR 5 3.75, 95% CI: 1.26-11.18). Only recently released genotyping platforms cover rs514148 or other SNPs in linkage disequilibrium (r 2 > 0.5). As per our knowledge, none of these SNPs were included in prior AD-genome-wide association studies, so we hope future studies will show whether rs514148 will be confirmed as an AD risk locus.
Since the genetic background alone could not explain the link between NLRP2 and AD, further factors, such as environmental exposure might have an additional impact on NLRP2 regulation in AD. We assessed whether prenatal tobacco smoke exposure as a known risk factors for AD 4,5 might play a role. Indeed, mediation analysis revealed that prenatal benzene exposure-a valid proxy for tobacco smoke exposure (see Fig E7 in Previously, in IFN-g stimulated hair follicle-derived keratinocytes from AD patients-mimicking an inflammatory response-an increased NLRP2 expression compared with that of healthy adults was observed.
3 This is in line with the immunosuppressive function of NLRP2 to blunt excessive nuclear factor-kB activation, as NLRP2 is a known nuclear factor-kB inhibitor. 1 Although, these results seem to contradict our findings, our observations were made in different cell types and at different time points (adulthood vs early childhood). More importantly, the small number of studied hair follicle-derived keratinocytes increases the likelihood that the genotype distribution determined the increased NLRP2 expression in AD patients. The results 
METHODS Whole blood and PBMC stimulation
Families with unidentified immunodeficiency were recruited for further evaluation with informed consent (National Health Service Research Ethics 09/H502/4). PBMC stimulation was performed as previously described. Whole blood was diluted 1:5 with RPMI into 96-well plates and activated by single stimulation or costimulations as indicated with IL-12 (20 ng/mL; R&D Systems, Abingdon, UK), PHA (10 mg/mL; Sigma-Aldrich, St Louis, Mo), LPS (1 mg/mL; List Biological Laboratories Inc, Campbell, Calif), LTA (50 mg/mL; Invivogen, San Diego, Calif), IFN-g (2 3 101 IU/mL, Immukin; Boehringer Ingelheim, Ingelheim am Rhein, Germany), IL-18 (20 ng/mL; R&D Systems), and BCG (3.4 3 104/well; Statens Serum Institut, Copenhagen, Denmark). Supernatants were taken at 24 hours. Cytokines were measured using standard ELISA according to the manufacturer's recommendations (IFN-g, Pelikine; Sanquin, Amsterdam, The Netherlands), or multiplexed particle-based flow cytometry (TNF-a, IL-12, IL-10; R&D Systems Fluorokinemap) on a Luminex analyzer (Bio-Plex, Bio-Rad Laboratories, Hercules, Calif). Bio-Rad Laboratories, Hercules, Calif). Beads were washed and stored in blocking buffer (10 mM PBS, 1% BSA, 0.05% NaN3). Cytokine-coupled beads were incubated with plasma or serum from patients for 1 hour in 96-well filter plates (MultiScreenHTS; Millipore, Burlington, Mass) at room temperature in the dark on a horizontal shaker. Fluids were aspirated with a vacuum manifold and beads were washed 3 times with 10 mM PBS/0.05% Tween 20. Beads were incubated for 30 minutes with a phycoerythrin-labeled antihuman IgG-Fc antibody (Leinco/Biotrend, Fenton, Mo), washed, and resuspended in 100 mL PBS/Tween. They were then analyzed on a Bioplex analyzer (Bio-Rad) using Bio-Plex Manager software.
ACAA determinations
Immunoblotting
PBMCs were incubated 6 anti-CD3 (10 mg/mL) (Clone OKT3; eBiosciences, Waltham, Mass) and 6 recombinant soluble CD70 (10 mg/mL; gift from Prof. A. Al-Shamkhani) overnight in complete medium. Cell lysates were corrected for protein concentrations via Bradford protein assay (Bio-Rad) before gel loading. For protein identification, the following antibodies from Cell Signaling were used: NF-kB2 p100/p52 (#4882). Mouse antihuman glyceraldehyde 3-phosphate dehydrogenase (ab845; Abcam, Cambridge, UK) was used as a whole-cell lysate loading control.
Exome sequencing
Exome enrichment was performed using the SureSelect Human All Exon V4.0 kit (Agilent, Santa Clara, Calif), before sequencing on the Illumina HiSeq 2000 system. Following sequencing, reads were aligned to GRCh37 (hg19) using NovoAlign v2.08.02, with duplicate reads flagged using Picard. Following alignment, variants were called using SAMtools v0.1.18. Called variants were annotated with functional effect predictions and population allele-frequencies using ANNOVAR (v2013Feb217).
Genotyping and Sanger sequencing
Genomic DNAwas isolated from PBMCs using DNeasy kit (Qiagen, Hilden, Germany), according to the manufacturer's instructions. Genomic DNA was then amplified with primers NFKB2_EX22F (CATCACCCCTCAT GGTCCTG) and NFKB2_EX22R (AAATAGGTGGGGACGCTGTA) using high-fidelity Phusion polymerase (Thermo Scientific, Inc, Waltham, Mass), according to manufacturer instructions. The presence of candidate mutation was confirmed by Sanger sequencing. 
FIG E2.
Whole-exome filtering of variants. 1, LRRC8A encodes a protein that functions as a volumeregulated anion channel by forming heteromers with other LRRC8 proteins. A single case of a patient with a de novo balanced t(9;20)(q33.2;q12) that resulted in a dominant negative-acting truncated LRRC8A protein is previously reported with the phenotype of agamaglobulinemia, absent B cells due to pre-B-cell arrest, and minor facial anomalies. E1 The missense variant LRRC8A:NM_001127245:exon2:c.G294T:p.K98N (PolyPhen 0.038:benign, SIFT 0.03:deleterious) present in both I.1 and II.2 is absent in the ExAC database; however, many missense variants in LRRC8A that are located near this variant are present in the ExAC database (http://exac.broadinstitute.org/gene/ENSG00000136802) at a frequency greater than expected for the reported phenotype. I.1 and II.2 do not display a similar phenotype to that reported for LRRC8A-dominant negative variants, E1 because they do not have pre-B-cell arrest, or agammaglobulinemia (Table E1) , or facial anomalies. It appears unlikely that this missense variant contributes the phenotype of I.1 or II.2. 2, NFKB2:NM_001077494:exon22:c.C2557T:p.R853X has been reported to cause an autosomal-dominant CVID with autoimmunity. E2 This variant segregated with disease and the clinical phenotype of autoimmunity including alopecia, trachonychia, and bronchiectasis is similar to that reported. 
